Barclays’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Barclays’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-45,770	Closed	-$2.47M	–	7585
2017 Q4	$2.47M	Sell	45,770 -52,588	-53%	-$2.88M	﹤0.01%	2251
2017 Q3	$5.61M	Buy	98,358 +55,164	+128%	+$3.23M	0.01%	1447
2017 Q2	$2.6M	Sell	43,194 -14,823	-26%	-$844K	﹤0.01%	2025
2017 Q1	$3.16M	Buy	+58,017	New	+$2.86M	﹤0.01%	1670

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Barclays's BIVV Position: Q1 2018 in Review

Barclays sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 45,770 shares — an estimated $2.47M sold.

Barclays first reported a position in BIVV in Q1 2017 and held it in 4 quarters. The position peaked at $5.61M in Q3 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Barclays reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Barclays sold 45,770 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $2.47M.
Barclays first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 4 quarters.
Barclays's Bioverativ Inc. Common Stock position peaked at $5.61M in Q3 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.